Form 4: Agenus CEO Garo Armen Boosts Stake with Stock-Based Salary

Agenus Inc. CEO Garo H. Armen received 3,769 shares of common stock as part of his salary, increasing his direct beneficial ownership.

Summary

• Garo H. Armen, Chairman and Chief Executive Officer of Agenus Inc., acquired 3,769 shares of Agenus Common Stock.
• This acquisition was a result of his salary being paid in stock, in lieu of cash, at his request and with the approval of the Agenus Inc. Compensation Committee.
• The shares were issued for the pay period ending November 14, 2025, and were fully vested upon issuance in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive Plan.
• The price per share was $4.34, which was the closing price of Agenus Common Stock on November 14, 2025.
• Following this transaction, Dr. Armen directly beneficially owns 294,498 shares and indirectly owns 60,248 shares (31,298 shares in IRA accounts and 28,950 shares through the Garo Armen 2020 2 Year AG GRAT and Pixie Partners).

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While a Form 4 is generally a factual report, a CEO opting for stock compensation instead of cash is often interpreted as a sign of confidence in the company's future, aligning management's interests with shareholders. This is a positive signal, though the transaction size is relatively small in the context of total shares outstanding.

Positives

• CEO Garo H. Armen's decision to take salary in stock demonstrates confidence in Agenus Inc.'s future prospects and aligns his interests further with shareholders.
• The shares were fully vested on the date of issuance, indicating immediate ownership and commitment.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash.

Industry Context

Insider stock acquisitions, particularly by a CEO, can signal management's confidence in the company's future performance, which is often viewed positively by the market. This aligns with a trend where executives in growth-oriented sectors, like biotechnology, opt for equity compensation to tie their personal wealth directly to shareholder value.

Comparison to Industry Standards

• While specific comparable companies or projects are not detailed in this filing, a CEO opting for stock-based compensation is a common practice across various industries, especially in biotechnology, to align executive incentives with long-term shareholder value.
• This move by Dr. Armen is consistent with best practices in corporate governance that encourage executive ownership and direct alignment with shareholder interests.

Related Party Transactions

• Garo H. Armen, as Chairman and CEO, received shares as salary, which is a transaction between an executive and the company.
• Dr. Armen is trustee and has investment authority for the Garo Armen 2020 2 Year AG GRAT, which holds 23,950 shares.
• Dr. Armen is a general partner in Pixie Partners, which owns 5,000 shares, and disclaims beneficial ownership to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders: The CEO's decision to take salary in stock may be viewed positively, signaling confidence and aligning management's interests with shareholder value.
• Management: The CEO's compensation structure is now more heavily weighted towards equity, tying his personal financial outcomes more closely to the company's stock performance.

Key Dates

Recommendation

This Form 4 filing indicates a routine insider transaction where the CEO opted for stock-based compensation. While this signals management confidence, the transaction size is not substantial enough on its own to warrant a 'buy' or 'sell' recommendation. It reinforces a 'hold' position for existing investors, as it suggests alignment of interests without providing new fundamental data to alter the investment thesis significantly.

Keywords

Agenus, AGEN, Garo Armen, Insider Trading, Form 4, Stock Compensation, CEO Stock Purchase, Beneficial Ownership, Equity Incentive Plan